相关实验视频

Updated: Jul 4, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

CD19 CAR-T细胞治疗复发性或耐火性扩散性大B细胞淋巴瘤:为什么会失败?

Hannah Kinoshita¹, Catherine M Bollard¹, Keri Toner¹

¹Cell Enhancement and Technologies for Immunotherapy, Children's National Hospital, Washington, DC; Department of Pediatrics, George Washington University, Washington, DC.

Seminars in hematology

|February 9, 2024

概括

卡特-T细胞疗法对扩散性大B细胞淋巴瘤 (DLBCL) 有希望,但许多患者复发. 本综述探讨了导致DLBCLCAR-T治疗失败的因素,有助于未来的治疗策略.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
细胞疗法细胞疗法

背景情况:

化学抗原受体T (CAR-T) 细胞疗法已批准用于复发/耐药的扩散大B细胞淋巴瘤 (DLBCL).
尽管有效,但很大一部分DLBCL患者 (高达60%) 在CAR-T治疗后经历疾病进展或复发.
在DLBCL中对CAR-T细胞疗法的耐药性背后的复杂机制仍然不完全理解.

研究的目的:

审查和讨论导致DLBCL中CAR-T细胞治疗失败的已识别的因素.
强调需要分析临床试验和现实世界的数据来预测患者的反应.
为了阐明DLBCL CAR-T疗法中的多因素耐药机制.

主要方法:

临床试验和真实世界数据的文献综述.
分析患者,瘤和与治疗相关的因素.
关于CAR-T抗性机制的当前知识的综合.

主要成果:

几个因素,包括患者特异性,瘤内在性和与治疗相关的因素,都与CAR-T治疗失败有关.
了解这些因素对于改善持久缓解率至关重要.
持续的数据分析对于完善预测模型至关重要.

结论:

针对DLBCL的CAR-T细胞疗法面临着由于抵抗机制的挑战.
对预测因素的进一步研究是必要的,以优化治疗结果.
确定耐药性因素将指导DLBCL更有效的治疗策略的开发.

关键词:

在CAR-T细胞疗法中.卡-T 衰竭,淋巴瘤 DLBCL DLBCL 是一个字母.

更多相关视频

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...